Nigeria’s listed pharmaceutical companies delivered a strong performance in the first quarter of 2026 as firms navigated a challenging operating environment marked by persistent inflationary pressures, rising healthcare demand, and global tension.
While revenue growth remained strong across much of the sector, the ability to convert sales into profits and generate returns for shareholders emerged as the key differentiator among industry players.
An analysis of the drugmakers’ firms listed on the Nigerian Stock Exchange, which include Fidson Healthcare Plc, MeCure Industries Plc, May & Baker Nigeria Plc, and Neimeth International Pharmaceuticals Plc, shows that their combined net profit margin rose by 9.98 percent in the first quarter of 2026, compared to 8.58 percent reported in the corresponding period of 2025.
In absolute terms, their combined profit rose to N7.2 billion in the first three months of the year, as against N5.06 billion reported in Q1 ’25. While revenue rose by 23 percent to N72.95 billion.
Profit margin is a financial ratio that measures the percentage of profit a company earns from its revenue. Expressed as a percentage, it indicates how much profit the company makes for every dollar of revenue generated.
